Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(15):1023; doi:10.1093/jnci/djj325
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Sequential Topotecan in Advanced Ovarian Cancer

The combination of carboplatin and paclitaxel is the standard of care for ovarian cancer treatment, yet rates of recurrence and death remain high. In a randomized phase III trial of 1308 patients, Pfisterer et al. (p. 1036) examined whether sequential administration of topotecan would improve overall survival, overall response, and progression-free survival in patients receiving carboplatin–paclitaxel as first-line treatment for advanced epithelial ovarian cancer. It did not. Moreover, sequential topotecan caused more hematologic toxic effects (requiring more supportive care) and infections. The authors conclude that carboplatin–paclitaxel alone should remain the standard . . . [Full Text of this Article]

Race-related Distribution and Persistence of HPV 16 and 18

Inconsistent Hospice Use Among Cancer Patients

SOX 18 Transcription Factor and Tumor Angiogenesis

Anti-Leukemia Activity of Shepherdin Molecule

Processed Meat Intake and Risk for Stomach Cancer

HIV-linked Nervous System Lymphoma and HAART


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?